Patients treated for uterine fibroids or adenomyosis typically return to their normal routine within twenty four hours of the procedure, a major improvement over most fibroid treatment techniques. A growing number of women have become pregnant following the ExAblate treatment. Studies have shown that MRgFUS may even improve fertility in women suffering from infertility caused by uterine fibroids.(1)
Experience at sites around the world has shown that ExAblate significantly increases patient interest in MRgFUS treatment and facility traffic. A leading site in Tokyo, Japan reported that the number of patients treated for uterine fibroids increased by 550% in one year.(2)
The ExAblate treatment has also been proven as a cost-effective alternative to current treatments, meeting acceptable criteria for optimal cost-effectiveness in fibroid treatment.(3)
"MR guided Focused Ultrasound (MRgFUS) use in the treatment of uterine fibroids has been an accepted and viable option for increasing numbers of women for several years now. However, with the enhancements offered by ExAblate(R) One we are able to offer even more women the option of treatment with an effective, dedicated women's health platform with predictable results." Said Professor Wladyslaw M Gedroyc, MD, Head of Radiology, St. Mary's Hospital, London, UK. "In addition to the benefits to patients, such as preservation of the uterus and improved chances of fertility, we have also seen a significant reduction in treatment time."
The ExAblate(R) OR platform is a Non-invasive Image Guided and Controlled
Acoustic Operating Room. The system incorporates interchangeable cradles for
each application that are interfaced with a single common table. ExAblate(R)
OR offers both commercially approved and research treatment options for a
multitude of clinical indications such as: uterine fibroids and adenomyosis,
breast cancer, prostate cancer, pain palliation of bone metastases and
|SOURCE InSightec Ltd|
Copyright©2010 PR Newswire.
All rights reserved